DDX / AKR1C3 Antibody (C-Terminus)
Goat Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC-P, E |
---|---|
Primary Accession | P42330 |
Reactivity | Human |
Host | Goat |
Clonality | Polyclonal |
Calculated MW | 37kDa |
Dilution | ELISA (1:32000), IHC-P (5 µg/ml), WB (1:32000) |
Gene ID | 8644 |
---|---|
Other Names | Aldo-keto reductase family 1 member C3, 1.-.-.-, 17-beta-hydroxysteroid dehydrogenase type 5, 17-beta-HSD 5, 3-alpha-HSD type II, brain, 3-alpha-hydroxysteroid dehydrogenase type 2, 3-alpha-HSD type 2, 1.1.1.357, Chlordecone reductase homolog HAKRb, Dihydrodiol dehydrogenase 3, DD-3, DD3, Dihydrodiol dehydrogenase type I, HA1753, Indanol dehydrogenase, 1.1.1.112, Prostaglandin F synthase, PGFS, 1.1.1.188, Testosterone 17-beta-dehydrogenase 5, 1.1.1.239, 1.1.1.64, Trans-1, 2-dihydrobenzene-1, 2-diol dehydrogenase, 1.3.1.20, AKR1C3, DDH1, HSD17B5, KIAA0119, PGFS |
Target/Specificity | Human AKR1C3. |
Reconstitution & Storage | Store at -20°C. Minimize freezing and thawing. |
Precautions | DDX / AKR1C3 Antibody (C-Terminus) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | AKR1C3 |
---|---|
Function | Cytosolic aldo-keto reductase that catalyzes the NADH and NADPH-dependent reduction of ketosteroids to hydroxysteroids. Acts as a NAD(P)(H)-dependent 3-, 17- and 20-ketosteroid reductase on the steroid nucleus and side chain and regulates the metabolism of androgens, estrogens and progesterone (PubMed:10622721, PubMed:11165022, PubMed:7650035, PubMed:9415401, PubMed:9927279). Displays the ability to catalyze both oxidation and reduction in vitro, but most probably acts as a reductase in vivo since the oxidase activity measured in vitro is inhibited by physiological concentration of NADPH (PubMed:14672942, PubMed:11165022). Acts preferentially as a 17- ketosteroid reductase and has the highest catalytic efficiency of the AKR1C enzyme for the reduction of delta4-androstenedione to form testosterone (PubMed:20036328). Reduces prostaglandin (PG) D2 to 11beta-prostaglandin F2, progesterone to 20alpha-hydroxyprogesterone and estrone to 17beta-estradiol (PubMed:15047184, PubMed:20036328, PubMed:10622721, PubMed:11165022, PubMed:10998348, PubMed:19010934). Catalyzes the transformation of the potent androgen dihydrotestosterone (DHT) into the less active form, 5-alpha-androstan-3-alpha,17-beta-diol (3-alpha-diol) (PubMed:10998348, PubMed:14672942, PubMed:11165022, PubMed:7650035, PubMed:9415401, PubMed:10557352). Also displays retinaldehyde reductase activity toward 9-cis-retinal (PubMed:21851338). |
Cellular Location | Cytoplasm. |
Tissue Location | Expressed in many tissues including adrenal gland, brain, kidney, liver, lung, mammary gland, placenta, small intestine, colon, spleen, prostate and testis. High expression in prostate and mammary gland. In the prostate, higher levels in epithelial cells than in stromal cells. In the brain, expressed in medulla, spinal cord, frontotemporal lobes, thalamus, subthalamic nuclei and amygdala. Weaker expression in the hippocampus, substantia nigra and caudate |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta- PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms androstenedione (4-dione) to testosterone.
References
Qin K.-N.,et al.J. Steroid Biochem. Mol. Biol. 46:673-679(1993).
Khanna M.,et al.J. Biol. Chem. 270:20162-20168(1995).
Khanna M.,et al.J. Steroid Biochem. Mol. Biol. 53:41-46(1995).
Lin H.-K.,et al.Mol. Endocrinol. 11:1971-1984(1997).
Suzuki-Yamamoto T.,et al.FEBS Lett. 462:335-340(1999).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.